Want to see AU:AN1 full AI Analyst Report?
Top Page
Anagenics
(Sydney:AN1)
Select Model
Select Model
Rating:53Neutral
Price Target:―
Action:Reiterated
Date:09/06/26
The score is primarily driven by the mixed financial picture: a meaningful return to profitability and very low leverage are positives, but ongoing negative operating/free cash flow and an uneven multi-year track record keep risk elevated. Valuation is also a mild headwind with a P/E of 30 and no dividend yield data. Technical signals could not be assessed due to missing indicator data.
Positive Factors
Return to profitability
The return to positive operating and net profit marks a meaningful earnings inflection after several loss-making years. If management sustains this improvement, stronger internal earnings can support reinvestment, improve resilience, and establish a more durable base for future growth.
Negative Factors
Negative cash generation
Persistent negative operating and free cash flow means reported profitability has not yet translated into self-funded operations. Continued cash burn can require use of balance-sheet resources or external capital, limiting strategic flexibility and making the recovery more vulnerable if conditions weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to profitability
The return to positive operating and net profit marks a meaningful earnings inflection after several loss-making years. If management sustains this improvement, stronger internal earnings can support reinvestment, improve resilience, and establish a more durable base for future growth.
Read all positive factors
Anagenics (AN1) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.91M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)30.0
Beta (1Y)1.15
Revenue Growth5.83%
EPS GrowthN/A
CountryAU
Employees11
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)<0.01
Shares Outstanding985,450,800
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.15
Price to Sales (P/S)0.94
P/FCF Ratio-4.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Anagenics Business Overview & Revenue Model
Company Description
Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It ...
How the Company Makes Money
null...
Anagenics Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.16M | 4.75M | 10.80M | 9.11M | 6.95M |
| Gross Profit | 2.81M | 2.04M | 4.36M | 4.05M | 3.80M |
| EBITDA | 816.06K | -994.77K | -6.60M | -1.80M | -2.62M |
| Net Income | 308.47K | -1.24M | -7.49M | -2.67M | -3.65M |
Balance Sheet | |||||
| Total Assets | 4.75M | 4.10M | 6.19M | 11.11M | 12.92M |
| Cash, Cash Equivalents and Short-Term Investments | 577.43K | 395.52K | 1.62M | 2.57M | 3.28M |
| Total Debt | 33.19K | 848.05K | 772.64K | 654.33K | 1.76M |
| Total Liabilities | 520.80K | 2.28M | 3.48M | 2.22M | 4.64M |
| Stockholders Equity | 4.23M | 1.83M | 2.71M | 8.90M | 8.29M |
Cash Flow | |||||
| Free Cash Flow | -1.09M | -1.58M | -1.84M | -1.83M | -2.59M |
| Operating Cash Flow | -1.07M | -1.58M | -1.74M | -1.78M | -2.55M |
| Investing Cash Flow | -24.95K | 0.00 | -197.90K | -1.51M | -968.20K |
| Financing Cash Flow | 1.28M | 345.41K | 993.72K | 2.56M | 73.31K |
Anagenics Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
53 Neutral | AU$5.91M | 30.00 | 9.49% | ― | 5.83% | ― | |
46 Neutral | AU$5.64M | -2.81 | -49.07% | ― | -33.53% | 42.98% | |
41 Neutral | AU$10.40M | -0.67 | -430.23% | ― | -50.64% | -72.00% | |
41 Neutral | AU$1.61M | -0.38 | -239.37% | ― | ― | ― | |
39 Underperform | AU$15.82M | -4.94 | 1795.70% | ― | 0.72% | -486.96% | |
39 Underperform | AU$6.99M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
AU:AN1
Anagenics
―
―
―
AU:EVE
EVE Health Group Limited
0.02
-0.01
-40.00%
AU:SKN
Skin Elements Limited
―
―
―
AU:HCT
Holista Colltech Limited
0.04
-0.06
-59.05%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
<0.01
5.00%
AU:HPC
Hydration Pharmaceuticals Co. Ltd.
0.01
0.00
0.00%
Anagenics Corporate Events
Anagenics Files Updated Corporate Governance Statement and Appendix 4G
Aug 28, 2026
Anagenics Limited has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming that the document is available on its website and has been approved by the board as at 27 August 2026. The filing, made together wi...
Anagenics Returns to Profit as Asset Backing Improves in FY26
Aug 28, 2026
Anagenics reported a modest 0.8% rise in revenue from ordinary activities to $5.16 million for the year ended 30 June 2026, while swinging to a net profit attributable to shareholders of $308,472 from a prior loss, reflecting a notable improvement...
Anagenics Nears Maiden Profit as Cash Flow and Royalty Revenue Improve
Jul 30, 2026
Anagenics reported continued improvement in operational performance for the June quarter, with operating cash outflows of $0.08 million and positive trading, and it expects to deliver a maiden full-year profit for FY26 subject to audit. Operating ...
Anagenics Appoints New Auditor Following ASIC-Approved Resignation
Jul 27, 2026
Anagenics Limited has announced a change of auditor, with the Australian Securities and Investments Commission consenting to the resignation of Connect National Audit Pty Ltd effective 24 July 2026. The company has appointed Stannards Audit Pty Lt...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.